SAMARITAN
EUROPE
Marketing, Sales, Clinical Trials
Samaritan
has established its European headquarters in Athens,
Greece which we believe will provide access to the markets
of Eastern Europe, Asia and Africa; These are regions
with a high proportion of HIV patients and a target
population for our most advanced drug, SP-01A.
The
main focus of Samaritan Europe (SE) will include:
European
Clinical Trials and Regulatory Approval
Samaritan Europe will be responsible for clinical trials,
and the regulatory approval, of all of its drug candidates
in Europe as a whole, with a focus on low-cost clinical
trials in southeast Europe, Asia, Africa and other countries.
Samaritan
Europe's first task will be to initiate Samaritan's
latest stage HIV drug through European clinical trials
and regulatory approval with the FDA's European counterpart,
the European Agency for the Evaluation of Medical Products
(EMEA).
However,
in the future, all cancer drug development and operations
will move to Europe where the laboratory will focus
on cancer drug and diagnostic candidates.
Marketing
and Distribution Arm
“Samaritan Pharmaceuticals Europe” intends
to develop a sales and marketing infrastructure in order
to market SP-01A and to cater to the needs of the under
serviced region of South Eastern and Central Eastern
Europe. SE plans to implement these plans by forming
agreements for niche high valued products from other
biotechnology companies. |
